• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Effect of Stem Cell Therapy on Patients' Quality of Life in Heart Failure with Reduced Ejection Fraction.干细胞疗法对射血分数降低的心力衰竭患者生活质量的影响。
J Med Life. 2018 Oct-Dec;11(4):359-364. doi: 10.25122/jml-2018-0013.
2
Heart Failure and Midrange Ejection Fraction: Implications of Recovered Ejection Fraction for Exercise Tolerance and Outcomes.心力衰竭与中等射血分数:射血分数恢复对运动耐量和预后的影响
Circ Heart Fail. 2016 Apr;9(4):e002826. doi: 10.1161/CIRCHEARTFAILURE.115.002826.
3
Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.射血分数降低的心力衰竭的恢复和结局:一项前瞻性研究。
Eur J Heart Fail. 2017 Dec;19(12):1615-1623. doi: 10.1002/ejhf.824. Epub 2017 Apr 6.
4
Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF).射血分数中间值的心衰:一种明确的临床实体?来自强化与标准药物治疗充血性心力衰竭老年患者的试验(TIME-CHF)的见解。
Eur J Heart Fail. 2017 Dec;19(12):1586-1596. doi: 10.1002/ejhf.798. Epub 2017 Mar 15.
5
Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain).伴有中间范围射血分数的心力衰竭患者的临床特征、射血分数一年变化及长期结局:在加泰罗尼亚(西班牙)进行的一项多中心前瞻性观察研究。
BMJ Open. 2017 Dec 21;7(12):e018719. doi: 10.1136/bmjopen-2017-018719.
6
Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction.左心衰竭射血分数保留与降低时的右心功能障碍。
Eur J Heart Fail. 2017 Dec;19(12):1664-1671. doi: 10.1002/ejhf.873. Epub 2017 Jun 8.
7
Variable Contribution of Heart Failure to Quality of Life in Ambulatory Heart Failure With Reduced, Better, or Preserved Ejection Fraction.射血分数降低、改善或保留的门诊心力衰竭中心力衰竭对生活质量的可变贡献。
JACC Heart Fail. 2016 Mar;4(3):184-93. doi: 10.1016/j.jchf.2015.12.011. Epub 2016 Feb 10.
8
Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.慢性心力衰竭伴射血分数保留、中间范围和降低患者的流行病学和一年结局:ESC 心力衰竭长期注册研究分析。
Eur J Heart Fail. 2017 Dec;19(12):1574-1585. doi: 10.1002/ejhf.813. Epub 2017 Apr 6.
9
Quality of life questionnaire predicts poor exercise capacity only in HFpEF and not in HFrEF.生活质量问卷仅能预测射血分数保留的心力衰竭(HFpEF)患者运动能力较差,而不能预测射血分数降低的心力衰竭(HFrEF)患者。
BMC Cardiovasc Disord. 2017 Oct 17;17(1):268. doi: 10.1186/s12872-017-0705-0.
10
Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome.左心室射血分数中等范围的急性心力衰竭:临床特征、住院治疗及短期预后
Clin Res Cardiol. 2017 May;106(5):359-368. doi: 10.1007/s00392-016-1063-0. Epub 2016 Dec 20.

引用本文的文献

1
Effects of comprehensive nursing intervention based on self-disclosure on improving alexithymia in elder patients with coronary heart disease.基于自我表露的综合护理干预对改善老年冠心病患者述情障碍的效果
BMC Nurs. 2022 Aug 5;21(1):216. doi: 10.1186/s12912-022-01006-w.
2
Can Stem Cells Improve Left Ventricular Ejection Fraction in Heart Failure? A Literature Review of Skeletal Myoblasts and Bone Marrow-Derived Cells.干细胞能否改善心力衰竭患者的左心室射血分数?骨骼肌成肌细胞和骨髓源细胞的文献综述
Cureus. 2020 Nov 20;12(11):e11598. doi: 10.7759/cureus.11598.

本文引用的文献

1
Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]).心力衰竭患者静脉输注脐带间充质干细胞的安全性和有效性:一项1/2期随机对照试验(RIMECARD试验[静脉输注脐带间充质干细胞治疗心脏病的随机临床试验])
Circ Res. 2017 Oct 27;121(10):1192-1204. doi: 10.1161/CIRCRESAHA.117.310712. Epub 2017 Sep 26.
2
Stem cell therapy for ischemic heart diseases.干细胞治疗缺血性心脏病。
Br Med Bull. 2017 Jan 1;121(1):135-154. doi: 10.1093/bmb/ldw059.
3
Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.用于晚期缺血性心力衰竭的心肌生成细胞疗法:前瞻性、随机、双盲、假手术对照的CHART-1临床试验39周结果
Eur Heart J. 2017 Mar 1;38(9):648-660. doi: 10.1093/eurheartj/ehw543.
4
Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial.静脉内同种异体间充质干细胞治疗非缺血性心肌病:一项 II-A 期随机试验的安全性和疗效结果。
Circ Res. 2017 Jan 20;120(2):332-340. doi: 10.1161/CIRCRESAHA.116.309717. Epub 2016 Nov 16.
5
Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial.异基因与自体间充质干细胞治疗非缺血性扩张型心肌病的随机对照研究:POSEIDON-DCM试验
J Am Coll Cardiol. 2017 Feb 7;69(5):526-537. doi: 10.1016/j.jacc.2016.11.009. Epub 2016 Nov 14.
6
Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial.Ixmyelocel-T 治疗缺血性心力衰竭患者的前瞻性随机双盲试验。
Lancet. 2016 Jun 11;387(10036):2412-21. doi: 10.1016/S0140-6736(16)30137-4. Epub 2016 Apr 5.
7
Clinical observation of umbilical cord mesenchymal stem cell treatment of severe systolic heart failure.脐带间充质干细胞治疗重度收缩性心力衰竭的临床观察
Genet Mol Res. 2015 Apr 10;14(2):3010-7. doi: 10.4238/2015.April.10.11.
8
Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial).骨髓间充质基质细胞治疗严重缺血性心力衰竭患者:一项随机安慰剂对照试验(MSC-HF 试验)。
Eur Heart J. 2015 Jul 14;36(27):1744-53. doi: 10.1093/eurheartj/ehv136. Epub 2015 Apr 29.
9
Development and Validation of the First Iranian Questionnaire to Assess Quality of Life in Patients With Heart Failure: IHF-QoL.首个用于评估心力衰竭患者生活质量的伊朗问卷(IHF-QoL)的开发与验证
Res Cardiovasc Med. 2012 Nov;1(1):10-6. doi: 10.5812/cardiovascmed.4186. Epub 2012 Nov 1.
10
Intracoronary stem cell infusion after acute myocardial infarction: a meta-analysis and update on clinical trials.急性心肌梗死后冠状动脉内干细胞输注:荟萃分析和临床试验更新。
Circ Cardiovasc Interv. 2014 Apr;7(2):156-67. doi: 10.1161/CIRCINTERVENTIONS.113.001009. Epub 2014 Mar 25.

干细胞疗法对射血分数降低的心力衰竭患者生活质量的影响。

Effect of Stem Cell Therapy on Patients' Quality of Life in Heart Failure with Reduced Ejection Fraction.

作者信息

Mostafavian Zahra, Vakilian Farveh, Torkmanzade Leila, Moghiman Toktam

机构信息

Department of Community Medicine, Mashhad Branch, Islamic Azad University, Mashhad, Iran.

Cardiothoracic Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

出版信息

J Med Life. 2018 Oct-Dec;11(4):359-364. doi: 10.25122/jml-2018-0013.

DOI:10.25122/jml-2018-0013
PMID:30894895
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6418329/
Abstract

Heart failure with reduced ejection fraction (HFrEF) is a debilitating disease in which Left Ventricular Ejection Fraction (LVEF) is ≤ 40%, and it involves various organs. Regarding the novelty of stem cell therapy in HF, we aimed at studying the effect of stem cell therapy on the QoL of patients with HFrEF. In a prospective study, 30 patients diagnosed with HFrEF who had undergone stem cell injection (study group) and 30 patients with HFrEF receiving guideline-directed medical therapy (control group) were recruited by convenience sampling during 2016 in Mashhad, Iran. Patients' quality of life, left ventricular ejection fraction and their disability degree were studied twice with a 3-month interval. For data analysis, paired t-test, chi2 and multivariate linear regression were used. The mean age of study and control groups was 61.3±10.24 and 60.93±7.88 years respectively. Ninety percent of the cases and 56.7% of the controls were male (P=0.003). A significant difference in QoL was observed before and after treatment in each group (P<0.05). However, the QoL score showed no statistical difference between the two groups following treatment (P=0.13). The same result was achieved for LVEF (P=0.18); whereas the NYHA function class showed a significant difference between the two groups following treatment (P=0.017). According to the results, it seems that the treatment of HFrEF patients with stem cells is as effective as conventional therapies in improving the LVEF and QoL and more efficient than conventional treatments in increasing the patients' general satisfaction with life.

摘要

射血分数降低的心力衰竭(HFrEF)是一种使人衰弱的疾病,其左心室射血分数(LVEF)≤40%,且累及多个器官。关于干细胞疗法在心力衰竭治疗中的创新性,我们旨在研究干细胞疗法对HFrEF患者生活质量(QoL)的影响。在一项前瞻性研究中,2016年于伊朗马什哈德通过便利抽样招募了30例诊断为HFrEF且接受过干细胞注射的患者(研究组)和30例接受指南指导药物治疗的HFrEF患者(对照组)。患者的生活质量、左心室射血分数及其残疾程度每隔3个月进行两次研究。数据分析采用配对t检验、卡方检验和多元线性回归。研究组和对照组的平均年龄分别为61.3±10.24岁和60.93±7.88岁。90%的研究组患者和56.7%的对照组患者为男性(P = 0.003)。每组治疗前后的QoL均有显著差异(P<0.05)。然而,治疗后两组之间的QoL评分无统计学差异(P = 0.13)。LVEF也得到了相同的结果(P = 0.18);而纽约心脏协会(NYHA)功能分级在治疗后两组之间存在显著差异(P =

0.017)。根据结果,干细胞治疗HFrEF患者在改善LVEF和QoL方面似乎与传统疗法一样有效,且在提高患者对生活的总体满意度方面比传统治疗更有效。